J Bellmunt1, J Dutcher. 1. Solid Tumor Oncology (GU & GI), Medical Oncology Service, University Hospital del Mar-IMIM, Barcelona, Spain. jbellmunt@parcdesalutmar.cat
Abstract
BACKGROUND: Targeted therapies have shown profound effects on the outcome of patients with advanced renal cell carcinoma (RCC). However, the optimal treatment for RCC of non-clear cell histology (nccRCC)-typically excluded from trials of targeted agents-remains uncertain. MATERIALS AND METHODS: By carrying out extensive searches of PubMed and ASCO databases, we identified and summarised research into the biological characteristics, clinical behaviour and treatment of different histological subtypes of nccRCC, focusing on targeted therapy. RESULTS: The available data suggest that treatments currently approved for RCC are active in ncc subtypes, although the overall clinical benefit may be less than for clear cell RCC. Temsirolimus has proven benefit over interferon-alfa (IFN-α) in patients with nccRCC, based on phase III data, while everolimus, sunitinib and sorafenib have all demonstrated some degree of activity in nccRCC in expanded-access trials. No clear picture has emerged of whether individual histological subtypes are particularly responsive to any individual treatment. CONCLUSIONS: Further molecular studies into the pathogenesis of RCC histological subtypes will help direct the development of novel, appropriate targeted agents. Clinical trials specifically designed to evaluate the role of targeted agents in nccRCC are ongoing, and data from trials with sunitinib and everolimus will be reported soon.
BACKGROUND: Targeted therapies have shown profound effects on the outcome of patients with advanced renal cell carcinoma (RCC). However, the optimal treatment for RCC of non-clear cell histology (nccRCC)-typically excluded from trials of targeted agents-remains uncertain. MATERIALS AND METHODS: By carrying out extensive searches of PubMed and ASCO databases, we identified and summarised research into the biological characteristics, clinical behaviour and treatment of different histological subtypes of nccRCC, focusing on targeted therapy. RESULTS: The available data suggest that treatments currently approved for RCC are active in ncc subtypes, although the overall clinical benefit may be less than for clear cell RCC. Temsirolimus has proven benefit over interferon-alfa (IFN-α) in patients with nccRCC, based on phase III data, while everolimus, sunitinib and sorafenib have all demonstrated some degree of activity in nccRCC in expanded-access trials. No clear picture has emerged of whether individual histological subtypes are particularly responsive to any individual treatment. CONCLUSIONS: Further molecular studies into the pathogenesis of RCC histological subtypes will help direct the development of novel, appropriate targeted agents. Clinical trials specifically designed to evaluate the role of targeted agents in nccRCC are ongoing, and data from trials with sunitinib and everolimus will be reported soon.
Authors: Steffen Durinck; Eric W Stawiski; Andrea Pavía-Jiménez; Zora Modrusan; Payal Kapur; Bijay S Jaiswal; Na Zhang; Vanina Toffessi-Tcheuyap; Thong T Nguyen; Kanika Bajaj Pahuja; Ying-Jiun Chen; Sadia Saleem; Subhra Chaudhuri; Sherry Heldens; Marlena Jackson; Samuel Peña-Llopis; Joseph Guillory; Karen Toy; Connie Ha; Corissa J Harris; Eboni Holloman; Haley M Hill; Jeremy Stinson; Celina Sanchez Rivers; Vasantharajan Janakiraman; Weiru Wang; Lisa N Kinch; Nick V Grishin; Peter M Haverty; Bernard Chow; Julian S Gehring; Jens Reeder; Gregoire Pau; Thomas D Wu; Vitaly Margulis; Yair Lotan; Arthur Sagalowsky; Ivan Pedrosa; Frederic J de Sauvage; James Brugarolas; Somasekar Seshagiri Journal: Nat Genet Date: 2014-11-17 Impact factor: 38.330
Authors: Andrew T Lenis; Nicholas M Donin; David C Johnson; Izak Faiena; Amirali Salmasi; Alexandra Drakaki; Arie Belldegrun; Allan Pantuck; Karim Chamie Journal: J Urol Date: 2017-05-04 Impact factor: 7.450
Authors: Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri Journal: Eur Urol Date: 2015-11-26 Impact factor: 20.096
Authors: Magdalena M Bajer; Michael M Kunze; Johanna S Blees; Heidi R Bokesch; Hanyong Chen; Thilo F Brauss; Zigang Dong; Kirk R Gustafson; Ricardo M Biondi; Curtis J Henrich; James B McMahon; Nancy H Colburn; Tobias Schmid; Bernhard Brüne Journal: Biochem Pharmacol Date: 2014-02-07 Impact factor: 5.858
Authors: T K Choueiri; A P Fay; K P Gray; M Callea; T H Ho; L Albiges; J Bellmunt; J Song; I Carvo; M Lampron; M L Stanton; F S Hodi; D F McDermott; M B Atkins; G J Freeman; M S Hirsch; S Signoretti Journal: Ann Oncol Date: 2014-09-05 Impact factor: 32.976
Authors: Andrew W Silagy; Jessica Flynn; Roy Mano; Kyle A Blum; Julian Marcon; Renzo G DiNatale; Alejandro Sanchez; Maria I Carlo; Robert J Motzer; Jonathan A Coleman; Paul Russo; Irina Ostrovnaya; Yingbei B Chen; Ari A Hakimi Journal: Urol Oncol Date: 2019-09-12 Impact factor: 3.498